Clinical commissioning policy: Bendamustine with rituximab for first line treatment of advanced indolent non-Hodgkin’s lymphoma (all ages)

Document first published:
Page updated:
Topic:
,
Publication type:

This policy document outlines the arrangements for funding of treatment for first line treatment of advanced indolent non-Hodgkin’s lymphoma.